NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
CrisisInfrastructureStrikesIranTrumpNuclearFebruaryNewsMilitaryReachedLimitedDigestTimelineTrump'sDaysAnnounceDailyTariffsProtestsGreenlandChallengeEuropeanLongevityEmergency
CrisisInfrastructureStrikesIranTrumpNuclearFebruaryNewsMilitaryReachedLimitedDigestTimelineTrump'sDaysAnnounceDailyTariffsProtestsGreenlandChallengeEuropeanLongevityEmergency
All Articles
Estée Lauder CEO: Open to More M&A
Bloomberg
Clustered Story
Published about 4 hours ago

Estée Lauder CEO: Open to More M&A

Bloomberg · Feb 23, 2026 · Collected from RSS

Summary

"We will always be part of the M&A discussion," says Stéphane de La Faverie, CEO of The Estée Lauder Companies, as the company explores different strategies to rebuild profitability and regain market share. He spoke to Bloomberg's Francine Lacqua on "The Pulse." (Source: Bloomberg)

Share this story
Read Original at Bloomberg

Related Articles

Bloombergabout 6 hours ago
Estée Lauder Eyes M&A Opportunities to Help Turnaround, CEO Says

Estée Lauder Cos. is open to acquisitions as the owner of the Jo Malone and Le Labo brands enters the second year of a turnaround plan under Chief Executive Officer Stéphane de La Faverie.

Bloombergabout 1 hour ago
US Factory, Durable Goods Orders Declined in December

US Factory orders fell 0.7% in December, US Census Bureau data show, while durable goods orders were down 1.4%. Michael McKee reports on Bloomberg Television. (Source: Bloomberg)

Bloombergabout 1 hour ago
Italy’s F2i Fund Nears €1 Billion on Europe Infrastructure Push

F2i SGR, Italy’s largest independent infrastructure fund manager, brought its credit assets close to €1 billion ($1.2 billion) as demand grows for private financing to modernize European infrastructure.

Bloombergabout 2 hours ago
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Bloombergabout 2 hours ago
Alison Roman’s Plan to Conquer the Tomato Sauce Market

Alison Roman is a cult figure in the world of food media. Now she's putting her name on consumer goods, recently launching a new line of high-end jarred tomato sauce called, appropriately, A Very Good Sauce. Alison Roman joins Tracy Alloway and Joe Weisenthal on the Odd Lots podcast to discuss what she's learned about the consumer goods industry, from shipping to co-packing to designing a recipe that can be cooked in high volume. (Source: Bloomberg)

Bloombergabout 2 hours ago
Colombia Hawkish Pivot Masks Underlying Woes for Peso

Colombia’s peso is defying economic and political woes after a surprisingly hawkish pivot in monetary policy reinforced the dominant carry trade.